ABIOMED Inc.

350.95+1.99+0.57%Vol 32.58K1Y Perf 35.14%
Sep 23rd, 2021 13:02 DELAYED
BID350.97 ASK351.43
Open351.55 Previous Close348.96
Pre-Market- After-Market-
 - -%  - -
Target Price
387.33 
Analyst Rating
Moderate Buy 2.19
Potential %
10.37 
Finscreener Ranking
★★     46.07
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★★     47.88
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★★★★     69.11
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
74.80 
Earnings Rating
Sell
Market Cap15.93B 
Earnings Date
4th Nov 2021
Alpha0.01 Standard Deviation0.12
Beta1.31 

Today's Price Range

350.32353.79

52W Range

242.73387.40

5 Year PE Ratio Range

21.20260.10

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Buy
Performance
1 Week
-2.49%
1 Month
-0.81%
3 Months
8.47%
6 Months
16.86%
1 Year
35.14%
3 Years
-9.33%
5 Years
182.49%
10 Years
3 220.27%

TickerPriceChg.Chg.%
ABMD350.951.99000.57
AAPL146.730.88000.60
GOOG2 839.6520.88000.74
MSFT299.921.34000.45
XOM57.081.87003.39
WFC48.081.00002.12
JNJ165.611.68001.02
FB345.882.67000.78
GE104.005.46005.54
JPM161.385.47003.51
ProfitabilityValueIndustryS&P 500US Markets
81.70
28.00
30.70
28.60
16.78
RevenueValueIndustryS&P 500US Markets
935.26M
20.61
8.93
18.81
Earnings HistoryEstimateReportedSurprise %
Q01 20221.061.103.77
Q04 20211.101.2412.73
Q03 20211.151.171.74
Q02 20210.871.0116.09
Q01 20210.210.58176.19
Q04 20200.961.004.17
Q03 20201.091.111.83
Q02 20200.931.0310.75
Earnings Per EndEstimateRevision %Trend
9/2021 QR0.98-3.92Negative
12/2021 QR1.11-2.63Negative
3/2022 FY4.18-4.78Negative
3/2023 FY5.302.32Positive
Next Report Date4th Nov 2021
Estimated EPS Next Report0.98
Estimates Count7
EPS Growth Next 5 Years %20.00
Volume Overview
Volume32.58K
Shares Outstanding45.38M
Shares Float39.65M
Trades Count2.23K
Dollar Volume103.09M
Avg. Volume267.70K
Avg. Weekly Volume238.30K
Avg. Monthly Volume183.57K
Avg. Quarterly Volume197.08K

ABIOMED Inc. (NASDAQ: ABMD) stock closed at 348.96 per share at the end of the most recent trading day (a 1.15% change compared to the prior day closing price) with a volume of 174.76K shares and market capitalization of 15.93B. Is a component of S&P 500, Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 1536 people. ABIOMED Inc. CEO is Michael R. Minogue.

The one-year performance of ABIOMED Inc. stock is 35.14%, while year-to-date (YTD) performance is 7.64%. ABMD stock has a five-year performance of 182.49%. Its 52-week range is between 242.73 and 387.4, which gives ABMD stock a 52-week price range ratio of 74.80%

ABIOMED Inc. currently has a PE ratio of 105.30, a price-to-book (PB) ratio of 12.32, a price-to-sale (PS) ratio of 16.86, a price to cashflow ratio of 54.30, a PEG ratio of 2.32, a ROA of 11.12%, a ROC of 12.82% and a ROE of 12.50%. The company’s profit margin is 16.78%, its EBITDA margin is 30.70%, and its revenue ttm is $935.26 Million , which makes it $20.61 revenue per share.

Of the last four earnings reports from ABIOMED Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.98 for the next earnings report. ABIOMED Inc.’s next earnings report date is 04th Nov 2021.

The consensus rating of Wall Street analysts for ABIOMED Inc. is Moderate Buy (2.19), with a target price of $387.33, which is +10.37% compared to the current price. The earnings rating for ABIOMED Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

ABIOMED Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

ABIOMED Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 14.95, ATR14 : 8.97, CCI20 : -127.61, Chaikin Money Flow : 0.03, MACD : 1.98, Money Flow Index : 27.19, ROC : -6.37, RSI : 47.29, STOCH (14,3) : 18.54, STOCH RSI : 0.34, UO : 50.40, Williams %R : -81.46), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of ABIOMED Inc. in the last 12-months were: Andrew J. Greenfield (Option Excercise at a value of $662 500), Andrew J. Greenfield (Sold 34 312 shares of value $11 104 551 ), David M. Weber (Option Excercise at a value of $300 950), David M. Weber (Sold 13 000 shares of value $4 019 635 ), Dorothy E. Puhy (Sold 5 000 shares of value $1 747 347 ), Martin P. Sutter (Sold 24 900 shares of value $7 501 672 ), Michael R. Minogue (Option Excercise at a value of $1 967 750), Michael R. Minogue (Sold 85 000 shares of value $28 913 282 ), Paul G. Thomas (Sold 663 shares of value $219 301 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
4 (44.44 %)
4 (44.44 %)
4 (50.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
4 (44.44 %)
4 (44.44 %)
3 (37.50 %)
Moderate Sell
1 (11.11 %)
1 (11.11 %)
1 (12.50 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
2.19
Moderate Buy
2.19
Moderate Buy
2.09

ABIOMED Inc.

Abiomed Inc provides temporary mechanical circulatory support devices that are primarily used by interventional cardiologists and heart surgeons. The firm's products are used for patients in need of hemodynamic support before, during, or after angioplasty and heart surgery procedures. Abiomed receives the majority of revenue from its Impella product portfolio, which includes percutaneous micro heart pumps with integration motors and sensors and percutaneous catheter-based axial flow pumps. Abiomed generates the majority of its revenue in the United States.

CEO: Michael R. Minogue

Telephone: +1 978 646-1400

Address: 22 Cherry Hill Drive, Danvers 01923, MA, US

Number of employees: 1 536

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

59%41%

Bearish Bullish

58%42%

Bearish Bullish

59%41%

TipRanks News for ABMD

News

Stocktwits